JP Patent

JP2021521242A — アピキサバン製剤

Assigned to Bristol Myers Squibb Co · Expires 2021-08-26 · 5y expired

What this patent protects

アピキサバン医薬製剤が提供される。血栓塞栓性障害の治療における前記アピキサバン製剤の使用もまた提供される。【選択図】なし

USPTO Abstract

アピキサバン医薬製剤が提供される。血栓塞栓性障害の治療における前記アピキサバン製剤の使用もまた提供される。【選択図】なし

Drugs covered by this patent

Patent Metadata

Patent number
JP2021521242A
Jurisdiction
JP
Classification
—
Expires
2021-08-26
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.